Follow
Richard Aplenc
Richard Aplenc
Verified email at email.chop.edu
Title
Cited by
Cited by
Year
Chimeric antigen receptor T cells for sustained remissions in leukemia
SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ...
New England Journal of Medicine 371 (16), 1507-1517, 2014
56352014
Chimeric antigen receptor–modified T cells for acute lymphoid leukemia
SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ...
New England Journal of Medicine 368 (16), 1509-1518, 2013
40082013
Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
DT Teachey, SF Lacey, PA Shaw, JJ Melenhorst, SL Maude, N Frey, ...
Cancer discovery 6 (6), 664-679, 2016
9742016
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
DT Teachey, SR Rheingold, SL Maude, G Zugmaier, DM Barrett, AE Seif, ...
Blood, The Journal of the American Society of Hematology 121 (26), 5154-5157, 2013
6572013
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase …
AS Gamis, TA Alonzo, S Meshinchi, L Sung, RB Gerbing, SC Raimondi, ...
Journal of Clinical Oncology 32 (27), 3021, 2014
4392014
Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury
JM Marzec, JD Christie, SP Reddy, AE Jedlicka, H Vuong, PN Lanken, ...
The FASEB Journal 21 (9), 2237-2246, 2007
4152007
Collaborative efforts driving progress in pediatric acute myeloid leukemia
CM Zwaan, EA Kolb, D Reinhardt, J Abrahamsson, S Adachi, R Aplenc, ...
Journal of clinical oncology 33 (27), 2949, 2015
3682015
Low-dose, high-frequency CPR training improves skill retention of in-hospital pediatric providers
RM Sutton, D Niles, PA Meaney, R Aplenc, B French, BS Abella, ...
Pediatrics 128 (1), e145-e151, 2011
3012011
Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant …
N Bunin, R Aplenc, N Kamani, K Shaw, A Cnaan, S Simms
Bone marrow transplantation 32 (6), 543-548, 2003
2342003
Genetic variants associated with cancer therapy–induced cardiomyopathy
P Garcia-Pavia, Y Kim, MA Restrepo-Cordoba, IG Lunde, H Wakimoto, ...
Circulation 140 (1), 31-41, 2019
2302019
Nucleotide Substitution in the Ectodomain of TRAIL Receptor DR4 Is Associated with Lung Cancer and Head and Neck Cancer
MJ Fisher, AK Virmani, L Wu, R Aplenc, JC Harper, SM Powell, ...
Clinical cancer research 7 (6), 1688-1697, 2001
2172001
Epidemiology of childhood acute myeloid leukemia
SE Puumala, JA Ross, R Aplenc, LG Spector
Pediatric blood & cancer 60 (5), 728-733, 2013
2072013
Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia
R Aplenc, J Thompson, P Han, M La, H Zhao, B Lange, T Rebbeck
Cancer research 65 (6), 2482-2487, 2005
2062005
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
RJ Arceci, J Sande, B Lange, K Shannon, J Franklin, R Hutchinson, ...
Blood 106 (4), 1183-1188, 2005
1892005
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
KL Bride, TL Vincent, SY Im, R Aplenc, DM Barrett, WL Carroll, R Carson, ...
Blood, The Journal of the American Society of Hematology 131 (9), 995-999, 2018
1872018
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.
SL Maude, DT Teachey, SR Rheingold, PA Shaw, R Aplenc, DM Barrett, ...
Journal of Clinical Oncology 34 (15_suppl), 3011-3011, 2016
1712016
Durable remissions in children with relapsed/refractory all treated with t cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)
SA Grupp, SL Maude, PA Shaw, R Aplenc, DM Barrett, C Callahan, ...
Blood 126 (23), 681, 2015
1622015
CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer
C Zeigler-Johnson, T Friebel, AH Walker, Y Wang, E Spangler, ...
Cancer research 64 (22), 8461-8467, 2004
1462004
CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531
JK Lamba, L Chauhan, M Shin, MR Loken, JA Pollard, YC Wang, RE Ries, ...
Journal of Clinical Oncology 35 (23), 2674, 2017
1452017
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group
R Aplenc, TA Alonzo, RB Gerbing, FO Smith, S Meshinchi, JA Ross, ...
Blood 108 (1), 74-80, 2006
1442006
The system can't perform the operation now. Try again later.
Articles 1–20